Chemical inhibitors of BTBD6 work primarily by interfering with the ubiquitin-proteasome system (UPS), which is crucial for the degradation of proteins, thereby indirectly inhibiting the function of BTBD6, which plays a role in tagging proteins for degradation. Epoxomicin, MG-132, Lactacystin, Bortezomib, Carfilzomib, Oprozomib, Marizomib, and Velcade are all inhibitors that target the proteasome. These inhibitors prevent the proteasome from degrading ubiquitinated proteins, which could include substrates of BTBD6. This leads to the accumulation of these proteins within the cell, effectively inhibiting the function of BTBD6 in the degradation pathway. Velcade, specifically, prevents the proteasome from breaking down proteins that may be substrates of BTBD6, while Marizomib binds irreversibly to the proteasome, which impacts the turnover of proteins regulated by BTBD6.
Further indirect inhibition comes from chemicals like MLN4924, which inhibits the NEDD8-activating enzyme, disrupting the neddylation processes that BTBD6 could be involved in. Disruption of this process can subsequently inhibit the function of BTBD6 as the proteins that require neddylation for their degradation pathway remain unprocessed. PYR-41 targets the ubiquitin-activating enzyme E1, leading to a reduction in the ubiquitination of substrates that BTBD6 targets for degradation. This reduction in ubiquitination directly inhibits the functional activity of BTBD6 as fewer substrates are tagged for degradation. Lastly, IU1 inhibits the deubiquitinating enzyme USP14, which can enhance the degradation of proteins tagged by BTBD6, inversely inhibiting BTBD6 function by accelerating the removal of its substrates. Clasto-Lactacystin β-lactone also plays a role in inhibiting the proteasome, leading to the accumulation of proteins that BTBD6 would normally mark for degradation, thus inhibiting BTBD6's role in protein turnover. Through these mechanisms, these chemicals exert inhibitory effects on BTBD6 by disrupting the cellular pathways it is involved in, without affecting the protein directly.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Inhibits the proteasome, thus preventing degradation of ubiquitinated proteins, potentially including BTBD6 substrates. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Blocks proteasome activity, leading to an accumulation of BTBD6 substrates, indirectly inhibiting BTBD6 function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Specifically inhibits the proteasome, which could lead to an accumulation of BTBD6 substrates due to impaired degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can lead to increased levels of proteins that require BTBD6 for ubiquitination and degradation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Inhibits the 20S proteasome, potentially affecting the degradation pathway of proteins regulated by BTBD6. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Inhibits the proteasome, thereby potentially disrupting the degradation of BTBD6-regulated proteins. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits NEDD8-activating enzyme, which can disrupt neddylation processes involving BTBD6. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Inhibits ubiquitin-activating enzyme E1, potentially reducing BTBD6-mediated ubiquitination of substrates. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
Inhibits deubiquitinating enzyme USP14, potentially enhancing the degradation of BTBD6 substrates. | ||||||